Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.

Three experts discuss how computational pathology can enhance diagnosis and treatment in NSCLC.

Expert faculty discuss antibody–drug conjugates (ADCs) in NSCLC with brain metastases, reviewing the clinical trial evidence, practical patient selection and sequencing alongside local CNS therapies, and the emerging pipeline of investigational ADCs.

Case-based expert insights on diagnosis, monitoring and individualized management in LOPD.

This three-part series covers managing advanced NSCLC after EGFR-TKI therapy, highlighting new treatments, biomarkers and MDT-based care.
Three experts discuss how computational pathology can enhance diagnosis and treatment in NSCLC.
Expert faculty discuss antibody–drug conjugates (ADCs) in NSCLC with brain metastases, reviewing the clinical trial evidence, practical patient selection and sequencing alongside local CNS therapies, and the emerging pipeline of investigational ADCs.
Case-based expert insights on diagnosis, monitoring and individualized management in LOPD.
This three-part series covers managing advanced NSCLC after EGFR-TKI therapy, highlighting new treatments, biomarkers and MDT-based care.
Expert case discussions on PAH focusing on diagnosis, risk assessment and treatment strategies.
Expert insights on the practical application of immunotherapy in early-stage NSCLC
Watch an expert discuss the key clinical questions surrounding currently approved RET inhibitors in NSCLC.
In this symposium, three lung cancer specialists share their insights on TROP2-targeted ADCs in NSCLC
Leading experts in Pompe disease explore key data from WMS 2024 and WORLDSymposium 2025.
Watch a lung cancer expert discuss the latest data for ADCs in NSCLC and their implications for clinical practice.
Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.
A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).
A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.
Watch two experts discuss the diagnosis, risk stratification and treatment of pulmonary arterial hypertension.
Two oncologists and a pathologist discuss the implications of HER2 targeting in solid tumours, with a focus on NSCLC.
An oncologist and a pathologist discuss HER2 testing and treatments for HER2-altered NSCLC.
Prof. Wakelee discusses the latest evidence on immunotherapy for early-stage, resectable NSCLC.
Three experts discuss the pathogenesis, diagnosis and treatment for bronchiolitis obliterans syndrome (BOS).
touchRESPIRATORY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.